Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung

C. Roesel, K. Kambartel, U. Kopeika, A. Berzins, T. Voshaar, T. Krbek

Abstract


Pulmonary sarcomatoid carcinoma (psc) is a rare subtype of non-small-cell lung carcinoma with a poor prognosis and poor response to chemotherapy and radiotherapy. A previous study reported that psc expresses high levels of PD-L1, suggesting the potential efficacy of immune checkpoint inhibitors in these tumours. We report 2 cases of patients with a lung sarcomatoid carcinoma. Both patients initially underwent curative lung resection, but developed early recurrent disease. Because PD-L1 was highly expressed in the tumour cells, we initiated therapy with nivolumab, which showed good efficacy, almost complete radiologic tumour remission, and a remarkable improvement in the condition of those patients. Immune checkpoint inhibitors targeting PD-1 might be a valuable therapy option for pscs.


Keywords


Sarcomatoid carcinoma; lung cancer; immunotherapy; PD-L1 expression

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.26.4377






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)